By Corey J. Langer, MD, FACP Posted: December 11, 2019 Dr. Corey Langer Jennifer Temel, MD, and colleagues1 showed in a small but well-conducted phase III trial that a […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events